



Continuing education is jointly provided by Partners for Advancing Clinical Education (PACE) and Pharmacy Quality Alliance (PQA)

Please send all CE-related questions to [education@pqaalliance.org](mailto:education@pqaalliance.org).

### **Instructions for Credit**

To receive CE credit, learners must follow these steps at the conclusion of the conference:

1. Access the online evaluation for each session you attended.
2. Register for a login.
3. Complete the activity evaluation.
4. Upon completion of all evaluation questions, your credit will be submitted to CPE Monitor. Please check your NABP account within thirty (30) days to make sure the credit has posted.

**Pharmacists have until June 8, 2023, to complete the evaluation and claim credit.**

### **Target Audience**

This activity is intended for pharmacists.

### **Overall Conference Educational Objectives**

Upon completion of this activity, participants should be able to:

- Describe real-world examples of best practices to improve medication use quality.
- Explain how SDOH and health equity can be integrated into medication use services.
- Discuss examples of value-based payment models that include medication use services and options for improving their execution.
- Outline quality improvement strategies that can be used to improve Star Ratings.

### **Faculty and Disclosure of Conflicts of Interest**

PACE requires planners, faculty, and others who are in a position to control the content of this activity to disclose all financial relationships they may have with ineligible companies. All relevant financial relationships are thoroughly vetted and mitigated according to PACE policy. PACE is committed to providing learners with high-quality accredited CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The ***following faculty*** reported the following financial relationships or relationships to products or devices they have with ineligible companies:

- David Blaisdell - Employee: Real Chemistry
- Caroline Carney – Consultant/Advisor/Speaker: NeuroFlow, Arine; Individual Publicly Traded Stocks and Stock Options: NeuroFlow, Arine.
- Monica Littlejohn – Researcher: Sanofi

- David Medvedeff – Executive Role: Aspen RxHealth
- Kim Russo – Other: VUCA Health (Co-founder, shareholder, sold in 2021); Other (Co-Founder, shareholder): Aspen RxHealth
- Samuel Stolpe – Employee: Johnson & Johnson

All **other faculty** have no relevant financial relationship(s) to disclose with ineligible companies

The PACE planners and others have no relevant financial relationship(s) to disclose with ineligible companies. The PQA planners and others have no relevant financial relationship(s) to disclose with ineligible companies.

### **Joint Accreditation Statement**



In support of improving patient care, this activity has been planned and implemented by Partners for Advancing Clinical Education (PACE) and Pharmacy Quality Alliance (PQA). PACE is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

### **Pharmacy Continuing Education**

PACE designates this continuing education activity for 11.25 contact hours (1.125 CEUs) of the Accreditation Council for Pharmacy Education.

Type of Activity: Knowledge

Universal Activity Numbers:

- Impact of Applying SDOH on Prescription Fill Rate Analysis: JA4008073-9999-23-121-L99-P
- Using Technology to Drive Patient Care: JA4008073-9999-23-122-L99-P
- Integrating Pharmacists in Team-Based Care: Opportunity to Improve Health Outcomes: JA4008073-9999-23-123-L99-P
- Show Me the Data: Collect and Analyze Health Equity Data: JA4008073-9999-23-124-L99-P
- Pharmacy and Beyond: Advancing the Quality of Pharmacist-Provided Care by Optimizing Multidisciplinary Strategies: JA4008073-9999-23-125-L99-P
- Closing Behavioral Health Measurement Gaps in Medicare Quality Programs: JA4008073-9999-23-126-L99-P
- Overcoming Regulatory Constraints While Delivering Pharmacist-Provided Care and Services: JA4008073-9999-23-127-L99-P
- Advancing Health Equity in PBM Programs: JA4008073-9999-23-128-L99-P
- Medication Adherence: A Force Multiplier for Star Ratings Success: JA4008073-9999-23-129-L99-P
- Deprescribing: How to Ensure that Older Adults Take the Right Amount of Medications. Nothing More, Nothing Less: JA4008073-9999-23-130-L99-P
- One Size Does Not Fit All: Value-Based Pharmacy Payment Models in Practice: JA4008073-9999-23-131-L99-P
- Advancing the Quality of Oral Anticancer Medication Use: JA4008073-9999-23-132-L99-P
- Integrating Clinical Service Initiatives to Improve the Member Journey and Reduce Abrasion: JA4008073-9999-23-133-L99-P

- Population Health Strategies to Improve Health Outcomes and Reduce Medical Costs in the US Employer Group Sector: JA4008073-9999-23-134-L99-P
- Best Practices in Pharmacist Collaboration with Physicians and Payers to Improve Quality: JA4008073-9999-23-135-L99-P

### **Disclosure of Unlabeled Use**

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

### **Disclaimer**

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.